Search Results - "Nugnes, I"

Palonosetron for prevention of acute and delayed nausea and vomiting induced by moderately emetogenic adjuvant folfox-4 regimen in colorectal cancer (CRC) patients: A phase II study of the Gruppo Oncologico dell’ Italia Meridionale (GOIM) by Giuliani, F, Cilenti, G, Nugnes, I, Maiello, E, Di Bisceglie, M, Lorusso, V, Adamo, V, Colucci, G

“…Abstract Introduction Folfox-4 is the standard adjuvant treatment in stage III colon cancer and is also recommended in high-risk stage II colon cancer…”
Get full text

Epirubicin, taxotere and fluorouracil modulated by folinic acid in the treatment of advanced gastric cancer: A phase II study of the Gruppo Oncologico dell’ Italia Meridionale (GOIM) by Giuliani, F, Romito, S, Maiello, E, Capobianco, A, Carrozza, F, Nugnes, I, Misino, A, Valerio, M.R, Manzione, L, Colucci, G

“…Abstract Introduction Despite the large number of drugs active in AGC, no combination can be considered as the gold standard treatment. Modest increase have…”
Get full text

Bevacizumab + folfiri as first-line treatment in advanced colorectal cancer (ACC): A multicenter phase II study of the Gruppo Oncologico dell’ Italia Meridionale (prot. GOIM 2601) by Giuliani, F, Lorusso, V, De Vita, F, Cinieri, S, Maiello, E, Nugnes, I, del Prete, S, Orditura, M, Leo, S, Addeo, R, Colucci, G

Get full text

Folfiri versus xeliri in untreated advanced colorectal cancer: A phase II randomised trial of the Gruppo Oncologico dell’ Italia Meridionale (prot. GOIM 2405) by Giuliani, F, De Vita, F, Maiello, E, Nugnes, I, Di Bisceglie, M, Romito, S, Lorusso, V, Catalano, G, Agostara, B, Colucci, G

Get full text

FOLFIRI + bevacizumab as first-line treatment in advanced colorectal cancer (ACC): Final results (prot. GOIM 2601) by Giuliani, F., De Vita, F., Lorusso, V., Cinieri, S., Nugnes, I., Orditura, M., Maiello, E., Del Prete, S., Leo, S., Colucci, G.

“…Abstract only e15007 Background: The addition of Bev to IFL obtained better OS and RR than chemotherapy alone. However IFL is not considered an optimal regimen…”
Get full text

Bevacizumab + folfiri as first-line treatment in advanced colorectal cancer (ACC): A multicenter phase II study of the Gruppo Oncologico dell'Italia Meridionale (prot. GOIM 2601) by Colucci, G., Giuliani, F., Lorusso, V., De Vita, F., Cinieri, S., Maiello, E., Nugnes, I., Del Prete, S., Orditura, M., Leo, S., Addeo, R.

“…Abstract only…”
Get full text